Catalyst Pharm Inc (CPRX)

$6.91 0.26 (3.91%)

16:00 EDT CPRX Stock Quote Delayed 30 Minutes

7 of the Top-Rated Pharmaceutical Stocks for Q1

By Louis Navellier and the InvestorPlace Research Staff Jan 18, 2022

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks.

3 Low-Priced Stocks That Make Smart Bets

7 Penny Stocks That Wall Street Thinks Are Undervalued

7 Penny Stock Companies That Actually Make Money

Volume:

Previous Close -

Market Cap 710.21M

PE Ratio 16.45

EPS 0.42

Volume (Avg. Vol.) 1.54M

Day's Range $6.71 - $6.94

52-Week Range $4.81 - $8.65

Dividend & Yield N/A (N/A)

CPRX Stock Predictions, Articles, and Catalyst Pharm Inc News

From InvestorPlace
From the Web

Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold

By Chris Markoch Nov 3, 2020

Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk.

Why Catalyst Pharmaceuticals Stock Is Feeling the ‘Bern’

By Josh Enomoto, InvestorPlace Contributor Oct 20, 2020

Typically, a major clinical victory would boost names like Catalyst Pharmaceuticals stock. Unfortunately, some political rumblings and an unexpected competitor got in the way of CPRX.

9 Robinhood Stocks Flying Under the Radar

By Josh Enomoto, InvestorPlace Contributor Sep 14, 2020

Robinhood stocks have generated much attention this year, but here are some names that you may not have heard about.

4 Strong Buy Biotech Stocks With Upcoming FDA Decisions

By Harriet Lefton, Writer, TipRanks Oct 23, 2018

These biotech stocks have fast-approaching PDUFA dates. Biotechs can soar or plunge on FDA decisions. These four pharma stocks should soar.

26 Biotechnology Stocks to Sell Now

By Portfolio Grader Sep 19, 2016

The ratings of 26 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

23 Biotechnology Stocks to Sell Now

By Portfolio Grader Sep 12, 2016

The overall ratings of 23 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Stocks Celebrate GOP Win on Bipartisan Hopes

By Anthony Mirhaydari, InvestorPlace Market Strategist Nov 5, 2014

Now on the horizon: The ECB, payrolls and Friday's showdown between President Obama and congressional leaders.

5 Red-Hot Biotech Stocks to Buy

By Anthony Mirhaydari, InvestorPlace Market Strategist Oct 27, 2014

Investors have been chasing risk again, buying up biotech stocks. Here's our list of the best biotech stocks out there.

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

From Benzinga May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

BUILDING CYBER SANDCASTLES

Catalyst Pharm Inc (CPRX)

7 of the Top-Rated Pharmaceutical Stocks for Q1

3 Low-Priced Stocks That Make Smart Bets

7 Penny Stocks That Wall Street Thinks Are Undervalued

7 Penny Stock Companies That Actually Make Money

11 Best Stocks to Buy for 2022

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

BUILDING CYBER SANDCASTLES

Catalyst Pharm Inc (CPRX)

11 Best Stocks to Buy for 2022

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CPRX Stock Predictions, Articles, and Catalyst Pharm Inc News

Subscriber Sign in